Clinical trials: sponsored by Shanghai Chest Hospital
NSCLC
A Phase II Trial of Camrelizumab Combined With Famitinib for Adjuvant Treatment of Stage II-IIIA NSCLC.
This is a phase II, open-label, multi-cohort study, aiming to investigate safety and efficacy of Camrelizumab combined with famitinib for adjuvant treatment of stage II-IIIA non-small cell lung cancer with high-risk for relapse…
- Trial name
- CAMFA-L (NCT05005468)
- Testing
- Camrelizumab, Famitinib
- Where
- China
- Volunteers
- 61 people
- Sponsor
- Shanghai Chest Hospital
Esophageal Cancer
Anlotinib Combined With PD-1 Inhibitors for Advanced/Metastatic Esophageal Cancer
Efficacy and Safety of Anlotinib combined with PD-1 inhibitors as 2 or more lines treatment for Heavily Pretreated Patients With Advanced, Metastatic Squamous Cell Carcinoma of the Esophagus.
- Trial name
- APEC (NCT04984096)
- Volunteers
- 50 people
- Sponsor
- Shanghai Chest Hospital
Atrial Fibrillation
Termination of Persistent Atrial Fibrillation by Catheter Ablation
This is a prospective, multicenter, cohort study aims to demonstrate the role of termination of AF in ablation for persistent atrial fibrillation, and evaluate the clinical outcomes in patients with or without AF termination.
- Trial name
- NCT04958928
- Testing
- Catheter ablation
- Volunteers
- 400 people
- Sponsor
- Shanghai Chest Hospital
Lung Cancer, EGFR Gene Mutation
Almonertinib Treats Advanced NSCLC Patients With EGFR Mutations Who Are Safety Intolerant After Osimertinib Treatment
This is a prospective, multi-center, single-arm clinical trial to evaluate the safety and effectiveness of Almonertinib treatment in patients with EGFR mutation positive and advanced non-small cell lung cancer (NSCLC) who are…
- Trial name
- ACTIVE (NCT04882345)
- Testing
- Almonertinib
- Volunteers
- 40 people
- Sponsor
- Shanghai Chest Hospital
NSCLC
Almonertinib Versus Osimertinib in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases
This is a multicenter, randomized controlled, double-blind clinical trial. The study is designed to evaluate the efficacy and safety of high-dose Almonertinib versus Osimertinib in the second-line treatment of patients with EGFR…
- Trial name
- ATTACK (NCT04870190)
- Testing
- Almonertinib, Osimertinib
- Volunteers
- 232 people
- Sponsor
- Shanghai Chest Hospital
SCLC
Accelerated Hypofractionated vs. Conventionally Fractionated Concurrent CRT for LS-SCLC
This protocol is a phase III randomized controlled trial (RCT) evaluating the efficacy of induction chemotherapy followed by accelerated hypofractionated vs.
- Trial name
- NCT02990780
- Testing
- Conventionally fractionated concurrent chemo-radiotherapy, Accelerated hypofractionated concurrent chemo-radiotherapy
- Where
- China
- Volunteers
- 266 people
- Sponsor
- Shanghai Chest Hospital
NRG1-fused Non-small Cell Lung Cancer
To Evaluate the Efficacy of Afatinib in the Treatment of Locally Advanced/Metastatic Non-Small Cell Lung Cancer With NRG1 Fusion
This is an open-label, sing-arm, phase IV clinical study. The study is designed to evaluate the efficacy of Afatinib in treatment of NRG1-fused locally advanced/metastatic non-small cell lung cancer (NSCLC), and explore the…
- Trial name
- NCT04814056
- Testing
- Afatinib Dimaleate
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Shanghai Chest Hospital
Lung Ground-Glass Opacity
The Efficacy and Safety of TBCB vs TBFB in Diagnosis of GGO
The aim of this study is to investigate the difference of efficacy and safety between transbronchial cryobiopsy (TBCB) and transbronchial forceps biopsy (TBFB) in the diagnosis of lung ground-glass opacity.
- Trial name
- NCT04727190
- Testing
- Transbronchial Cryobiopsy, Transbronchial Forceps Biopsy
- Where
- China
- Volunteers
- 184 people
- Sponsor
- Shanghai Chest Hospital
Lung Cancer
ENB-guided Ablation Therapy Combined With VATS in the Treatment of MPLC
The study is designed as a prospective trial whose purpose is to evaluate the effectiveness and safety of ENB-guided ablation therapy combined with VATS in the treatment of multiple primary lung cancers (MPLC).
- Trial name
- NCT04730453
- Testing
- ENB-guided ablation therapy combined with VATS
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shanghai Chest Hospital
Non-small-cell Lung Cancer
Pyrotinib Plus Thalidomide in Advanced NSCLC Patients Harboring HER2 Exon 20 Insertions
Various driver gene mutations have been identified in lung cancer. Among them, human epidermal growth factor 2 (HER2) was identified in approximately 2% of non-small-cell lung cancers.
- Trial name
- NCT04382300
- Testing
- pyrotinib combined with thalidomide
- Where
- China
- Volunteers
- 39 people
- Sponsor
- Shanghai Chest Hospital
SCLC, Anlotinib
Anlotinib Plus Etoposide and Carboplatin as First-line Treatment for Extensive-stage Small Cell Lung Cancer
This is a phase II, open-label, single center study, aiming to investigate safety and efficacy of etoposide and carboplatin (administered intravenously) in combination with anlotinib (administered orally) in treatment-naive…
- Trial name
- NCT04684017
- Testing
- Anlotinib hydrochloride, Etoposide, Carboplatin
- Where
- China
- Volunteers
- 29 people
- Sponsor
- Shanghai Chest Hospital
Lung Cancer
NGS-based Comprehensive Genomic ctDNA Panel in NSCLC With Immunotherapy
Liquid biopsy based on next-generation sequencing (NGS) method has become an increasingly powerful detection tool for clinical research and practice.
- Trial name
- NCT04636047
- Testing
- The method of gene mutation detection
- Where
- China
- Volunteers
- 450 people
- Sponsor
- Shanghai Chest Hospital
Non-small Cell Lung Cancer Stage IIIA, Radiotherapy
To Evaluate the Role of Postoperative Radiotherapy in Patients With IIIA(N2) Non-Small Cell Lung Cancer
Rationale: Completely resected non-small cell lung cancer (NSCLC) patients with histologically confirmed N2 disease are a heterogeneous population, with 5-year survival rates ranging from 10% to 30%.
- Trial name
- NCT02977169
- Testing
- PORT, Platinum-based two drug chemotherapy (cisplatin/carboplatin + vinorelbine or cisplatin/carboplatin + pemetrexed regimen)
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Shanghai Chest Hospital
Lung Cancer
Rh-Endostatin Combined With CCRT(50 Gy) Followed by Durvalumab Maintenance for the Treatment of Specific Phase III NSCLC
A Study to Assess the Effects of Durvalumab following Rh-Endostatin combined with reduced-dose CCRT(50 Gy) in Patients with Stage III Unresectable Non-Small Cell Lung Cancer who can not tolerate 60 Gy irradiation.
- Trial name
- RELIEF (NCT04613284)
- Testing
- Recombinant human endostatin (Endostar), Thoracic irradiation of 50 Gy with 3DCRT or IMRT
- Volunteers
- 97 people
- Sponsor
- Shanghai Chest Hospital
Diagnoses Disease
Prediction Model of Peripheral Pulmonary Lesions Based on R-EBUS Image
Peripheral pulmonary lesions(PPLs) have a wide spectrum of diseases, and the diagnosis will affect the treatment strategy and prognosis.
- Trial name
- R-EBUS (NCT04497233)
- Where
- China
- Volunteers
- 1,300 people
- Sponsor
- Shanghai Chest Hospital
Adverse Reactions, Immune Checkpoint Inhibitor
Cardiac Adverse Reactions Related to Immune Checkpoint Inhibitor in NSCLC Patients
This is a prospective, open label, single arm study. A total of 300 patients with primary non-small cell lung cancer treated with PD-1/PD-L1 immune checkpoint inhibitors(ICIs) are expected to included .
- Conditions
- Adverse Reactions, Immune Checkpoint Inhibitor, Non-Small Cell Lung Cancer Patients, Cardiac Event
- Trial name
- NCT04473703
- Testing
- renin-angiotensin system inhibitors or angiotensin-receptor-neprilysin inhibitor
- Volunteers
- 300 people
- Sponsor
- Shanghai Chest Hospital
Lung Cancer
cfDNA Methylation Assay for Clinical Evaluation of Patients With Stage IA Lung Cancer After Ablation Operation
The objective is to screen and monitor the efficacy of cfDNA methylation in patients with stage I lung cancer after ablation, to compare the similarities and differences of cfDNA methylation between surgical treatment and…
- Trial name
- NCT04413656
- Testing
- ablation, surgery
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Shanghai Chest Hospital
Lymph Node Disease
Prediction Model of CP-EBUS in the Diagnosis of Lymph Nodes
Endobronchial ultrasound (EBUS) multimodal image including grey scale, blood flow doppler and elastography, can be used as non-invasive diagnosis and supplement the pathological result, which has important clinical application…
- Trial name
- NCT04328792
- Where
- China
- Volunteers
- 1,300 people
- Sponsor
- Shanghai Chest Hospital
Lung Cancer
Transbronchial Ablation for Peripheral Lung Tumor
The objective of the study was to evaluate the efficacy and safety of navigation bronchoscopy guided transbronchial ablation for the treatment of inoperable peripheral lung tumor.
- Trial name
- NCT02972177
- Testing
- Radiofrequency ablation, Microwave ablation
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Shanghai Chest Hospital
Esophageal Cancer, Esophageal Carcinoma
Robot-assisted Esophagectomy Versus Conventional Thoracoscopic Esophagectomy
This is the first randomized controlled study to compare the robot-assisted esophagectomy (RAE) to minimally invasive conventional thoracoscopic esophagectomy (CTE).
- Trial name
- RAE vs CTE (NCT03094351)
- Testing
- esophagectomy
- Where
- 6 sites in China
- Volunteers
- 360 people
- Sponsor
- Shanghai Chest Hospital